Recap: NeoGenomics Q3 Earnings

 

Shares of NeoGenomics NEO were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share fell 14.29% year over year to $0.06, which beat the estimate of $0.04.

Revenue of $125,444,000 higher by 19.84% year over year, which missed the estimate of $126,230,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

NeoGenomics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Oct 27, 2020

Time: 08:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1219/37902

Technicals

52-week high: $44.58

Company's 52-week low was at $19.67

Price action over last quarter: Up 11.78%

Company Description

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...